Hoth Therapeutics Deploys OpenAI API to Advance Development of Orphan HT-KIT Oncology Program March 10, 2026
Biodexa Announces Exclusive License of Otsuka’s OPB-171775, a Ph 1 ready Molecular Glue for GIST February 25, 2026
Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for GIST Patients February 1, 2026
FAILED TRIAL: Ph 3 STAR-221 study of domvanalimab-based combination in upper gastrointestinal cancers will be discontinued due to futility December 15, 2025
Positive Results Reported from Bezuclastinib PEAK Ph 3 Trial in Gastrointestinal Stromal Tumors (GIST) November 18, 2025
FDA Clears IND Application for Ziftomenib in Advanced Gastrointestinal Stromal Tumors (GIST) August 13, 2024
Enrollment in Ph 1/2 Study Discontinued; Development of THE-630 in Patients with GIST Terminated July 19, 2023
Positive Lead-In Data from Ongoing Ph 3 PEAK Trial of Bezuclastinib + Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST) announced June 6, 2023
QINLOCK® Included in NCCN Guidelines® for the Treatment of Second-Line GIST Patients and FDA Grants Breakthrough Therapy Designation for QINLOCK in Second-Line GIST Patients with Mutations in KIT Exon 11 and 17/18 March 31, 2023
Results from INTRIGUE Ph 3 Clinical Study Demonstrate Substantial Clinical Benefit of QINLOCK® in 2L GIST Patients with Mutations in KIT Exon 11 and 17/18 Only January 11, 2023
